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The covalent coupling ol’rH]LTAJ to human leukocyte LTAJ hydrolase is inhibited in a concentration-dependent fashion by pre-incubation with 
bcstatin. This inhibition correlated whh the concentration-dependent inhibition by bestatin of LTBJ and LTB, synthesis by LTAa hydrolnse. 
Epibestatin. a diastereomcr of bestatin. neither inhibited LTB, or LTBJ production by LTA, hydrolasc nor prcvcntud the eovalcnt coupling of 
[>H]LTA, to the enzyme. In contrast, captopril inhibited both LTB, synthesis by LTAa hydrolase and covalent couplingof[‘H]LTA, to the enzyme. 
LTA., hydrolase; Bestatin; [ZH]LTA, covalent coupling: Human leukocyte 
I. INTRODUCTION 
Leukotriene (LT)BJ is a product of activated leu- 
kocytes which has potent autocrine chernotactic and 
chemokinetic properties [l-3]. The synthesis of LTB, is 
catalysed by the enzyme LTA, hydrolase, which is a 
unique 70,000 Da cytosolic protein with no structural 
or functional similarities to other epoxide hydrolases 
[5-g]. LTAd and LTAS are the only epoxide substrates 
identified for LTAj hydrolase [lo]. LTA, has been 
shown to be a potent inhibitor which irreversibly inac- 
tivates the enzyme [I 11. Mechanism-based inactivation 
of LTA, hydrolase by LTA, itself occurs with covalent 
modification of the enzyme, which is stoichiometric 
with inactivation [ 121. In contrast o 5-lipoxygenase, the 
first committed enzyme in the leukotriene synthetic 
pathway, LTA, hydrolase is ubiquitously distributed in 
most tissues [13.14]. A zinc binding site in LTA., 
hydrolase was recently identified which has strong 
homology to that of aminopeptidases such as E. coli 
aminopeptidasc N and human kidney aminopeptidase 
M [ 15-171. LTA, hydrolase has been shown to contain 
1 mol of zinc per mole of enzyme and to have an 
intrinsic aminopeptidase activity in addition to its LTA, 
hydrolytic function [17,18]. The amino acid residues of 
LTA4 hydrolase involved in aminopeptidase activity 
and LTA4 hydrolysis have been proposed to be centred 
around the zinc binding domain since zinc is essential 
for both activities [IG-181. Pre-incubation of LTA., 
hydrolase with LTA4 also reduces both activities in ac- 
cordance with the model of one active site for both 
enzymatic activities [191. Furthermore, bestatin, a zinc 
aminopeptidase inhibitor, selectively and reversibly in- 
hibits both the aminopcptidase and the ETA, hydrolytic 
activities of LTA, hydrolase [30], Selective inhibition of 
LTB, and LTBS production and covalent coupling of 
[“HILTA, to human leukocyte LTA4 hydrolase by bes- 
tatin and captopril is presented in the following paper. 
The results visualize competition at a single active site 
of LTA4 hydrolase capable of both LTAI hydrolytic 
and aminopeptidase functions. 
2. MATERIALS AND METHODS 
~bh~virr/iorts: LT4>. S(S)-rrarfs-5.6-oxido-7,9-r~u~t~-l I-ris-eicosatc- 
traenoic acid; LTAA. 5(S)-rnels-5.6-oxido-7,9-rru~~~-l I, l4 cis-eicosate- 
tracnoic acid; LTA,, S(S)-rrurrs-5,6-oxido-7.9.l~urzs-I l,l4.17-cis-eico- 
sntetraenoic acid; LTB.,. 5(S).l2(R)-dil~ydroxy-8,1O-r~u~rs-6,14-cisei- 
cosutctracnoic acid. 
LTA, and LTA, methyl esters. LTB, (Merck Frosst). LTAs methyl 
ester (BioMol.), [14.15-‘HILTA methyl ester (42 Cilmmol) (Du Pont- 
New England Nuclear). prostaglandin B2. (PGB,). bovine serum nl- 
bumin (BSA). bestatin ((2S,3A)-3-amuto-2-hydroxy4phenylbu- 
tanoyl-L-lcucinc), epibcstatin (2?,3A)-3-amino-2-hydroxy4phenyl- 
butanoyl-L-leucinc), captopril ((?a-I-(J-mercapto-l-mcthyI- 
propionyl)-L-prolinc) (Sigma) and methanol of HPLC grade were 
used. Rainbow molecular weight markers were from Amersham. 
Sodium salts of LTAI. LTAl and [14,15-‘HILTA, wcrc prepared by 
saponilication of their methyl esters in methanol:10 N NaOH (9.5:O.k 
v/v) for I h at 20-25‘C. Human leukocyte LTA, hydrolase was 
purified 50-fold from freshly drawn blood by ammonium sulphatc 
precipitation (40-80%) and DEAE-5PW high pressure liquid chroma- 
tography (HPLC) fractionation as described previously [5]. The 
human leukocyte cytosol preparation used was me 30-608 am- 
monium sulphatc fraction from the 10,000 x g supematant of bunjl 
coat concentrates (Red Cross Montreal) prepared as described prcvi- 
ously [21]. Protein was dctcrmined by a modification of the method 
of Bradford [2]. 
Corrcs~o/&rce address: J.E. Evans, Department of Pharmacology, 
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2.2. L’I;I, lf~&oiuse uclii*iry assuys 
Human leukocyte cytosol(SOO~l ofa 3.2 mdml30-60% ammonium 
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sulphate.precipitated fraction) was pre+tcubated in a 500 ~1 total 
volume of 100 mM Tria-HCI. OH 8.0. I ma/ml BSA with either 5 ul 
dimethyl sulphoxide (DMSd)‘(control) 0; 5 ~1 of a 100.fold con- 
centrate of compound dissolved in DMSO for IO min at ?O-25°C. 
LTA, or LTAs (IOpM final concentration) was added and incubation 
continued for a further 10 min at 20-25°C. The reaction was tcr- 
minated by the addition of 0.5 ml of ethanol containing I nmol/ml 
PGB2. samples held on ice for IO min then centrifuged at 13.000 xg 
for 5 min at 4OC. A 100 ~1 aliquot of the supernatant was unalysed 
for LTBj formation by reverse phase HPLC on a C,, Waters Novapak 
column (3.9 x I50 mm) cluting isocratically at 0.8 ml/ruin with a 
70:30:0.1 (methunol:water:acetic a id) pH 5.4 solvent and monitoring 
absorbance of products at 270 run. PGB: internal standard clutcd at 
5.7 min, n/i-rrrrris-LTB,, epi-NN-rrrnls-LTB, and LTB., clutcd at 7.9, 8.8 
and IO.3 min. respectively. 
Partially pure human leukocyte LTAd hydrolase (40 HI of a 0.1 
mgml DEAE-SPW HPLC purilied fraction) or human leukocyte cy- 
tosol (40 ~1 of a 3.2 mgml 30-60% ammonium sulphate~prccipitatcd 
fraction) were pm-incubated in a 50 ~1 total volume of 200 mM 
Tris-HCI. pH 8.0 with citbcr 0.5 ~1 DMSO (control) or OS ~1 of a 
100.fold concentrate of compound in DMSO for IO min at 20-25°C. 
[‘HILTA, (440,000 dpm, 0.2 PCi, 0.1 PM final concentration) was 
added and incubation continued for a further IO min at 20-25°C. The 
reaction was terminated by the addition of Gpl of 100% TCA, samples 
held on ice for IO min then centrifugcxl al 13,000 x g for 5 min al 4°C. 
Pellets were washed once with IM) ~1 of I M Tris+lCI. pH 8.0. and 
resuspended in 50~1 ofn denaturing polyacrylamidc gel sample buffer 
containing 6.7 mM TrissHCl, pH 6.S.O.I3% sodium dodecyl sulphate, 
1.3% glycerol, 0.08 M ,%mcrcaptocthanol, and Bromophcnol blue. 
Samples were boiled for 2 min and I5 ~1 aliquots elecvophoresed on 
8 x 8 cm 8-l 6% or 10% polyacrylamide Novcx mini-gels according to 
the mctbod of Lacmmli [23]. Gels were tixed for I h in IO% methanol, 
10% acetic acid, enlightened, (Enlighten, Dupont NEN) for 30 min, 
dried at 50°C for 8 I? and exposed to Kodak XAR film in an intcnsify- 
ing cilssette for 48-120 h. Fluorographs were scanned using an LKB 
2202 laser densitomctrr for quantitation of radiolabeling of LTA., 
hydrolase The absorbance of the LTA, hydrolase bund in a boiled 
enzyme lane on each gel (enzyme boiled for 2 min prior to pre.incuba- 
tion with DMSO) was subtracted from the LTA, hydrolase band 
absorbances of other samples. The boiled enzyme control absorbance 
varied on different Ruorographs from O-254 of control [lH]LTA.I 
labeling. 
3. RESULTS 
Bestatin inhibited covalent coupling of [3H]LTA, to 
a partially purified preparation of human leukocyte 
LTAil hydrolase. Pre-incubation of the enzyme with 
100, 10 or 1 PM be&n resulted in approximately 90, 
50 or 20% inhibition of [‘H]LTA4 labeling of LTA4 
hydrolase, respectively. As shown in Fig. 1, pre-incuba- 
tion of the partially purified human leukocyte LT.44 
hydrolase preparation with 10 PM LTA3, an irreversible 
inhibitor of LTA., hydrolase [ll], resulted in approxi- 
mately 90% inhibition of [3H]LTAA labeling of the en- 
zyme. 
Uestatin inhibited LTB, formation by LTA, 
hydroiase in a human leukocyte cytosoi fraction in a 
concentration-dependent fashion with 50% inhibition of 
activity at approximately IOpM bestatin (Fig. 2). In this 
human leukocyte cytosolic preparation, [“HILTA la- 
10 1 10 100 
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Fig. I. Inhibition by bcstatin of[‘H]LTA, labclinyofparlittlly purified 
human leukocyte LTA, hydrolasc. Partially purilied human leukocyte 
LTA, hydrolase (40 ~1 of a 0.1 mg/ml DEAE-SPW HPLC purilicd 
fraction) was pre-incubated with either DMSO (control) (+). or IOpM 
LTAl (A& I, IO or 100 PM bcstatin. then incubated with 0,I PM 
[‘HILTA., as described in Materials and Methods. The intensity of the 
[‘H]LTAJ labcling of LTAJ hydrolase was quantitatcd by densito- 
metric analysis of the fluorograph and expressed as the % of control 
labeling. An aliquot of enzyme boiled for 2 min prior to pm-incubation 
with DMSO and [‘HILTA,, served as a boiled control (--). Positions 
of rainbow molecular weight markers (Amersham) are shown on the 
left. 
beling of LTAl hydrolase was also inhibited in a con- 
centration-dependent fashion by bestatin with 50% in- 
hibition of labeling at approximately 10 AM (Fig. 3). 
Similar results for bestatin inhibition of labeling were 
obtained using [3H]LTA, methyl ester instead of 
1 IQ 100 
Bestatin (uM) 
Fig, 2. Inhibition by bcstatin of LTB, formation by human leukocyte 
cytosol. A human leukocyte cytosol fraction (3060% ammonium 
sulphate-precipitated proteins) was pre-incubated with DMSO (con- 
trol) or varying concentrations of bcstatin in DMSO for 10 min at 
20-2YC. LTA, was added to a final concentration of 10 ,&I and 
following a further if! min incubation a: 23-25°C LTB., formaticn was 
dctcrmincd as described in Materials and Methods. Data is expressed 
as the % *of control LTB., formation and is the mean of duplicate 
determinations where the range was -t- 5%. The graph is representative 
of 2 such titrations. 
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Table I 
Selective inhibition of LTDJ or LTB5 lbrmalion by human lcukocytc 
LTA, hydrolasc 
8 Inhibition of LTB, or LT131 formation 
Inhibitor COW Bcstatin Epibcstatin Captopril 
luM) 
LTBJ LTBs LTBA LTBS LTBl 
100 85 ES 3 GO 
IO 47 3G II 
I I5 II 5 -4 
A human Icukocy~e cy~osol rraction (30-608 ammonium sulphatc- 
precipitated proteins including LTA, hydrolasc) was prc-incubated 
with 100, IO or I pM bcstatin, captopril, epibcstatin or DMSO (con- 
trol) for IO min at 30-75X. LTA, or LTA, was added to a linal 
concentration or IO ,uM and rollowing a rurthcr IO min incubation 
LTB, formation was dctcrmincd as dcscribcd in Matcrinls and 
Methods. Data is expressed as the 8 of control LTB, or LTB, forma- 
tion and is the mean of 2-4 dctcrminations where the range was ?17%. 
[3H]LTA, (data not shown). Less than 25% inhibition 
of [“HILTA, labeling of LTA4 hydrolase was see11 when 
100 PM bestatin was incubated for 10 min with the 
cytosol after covalent coupling of the [‘HILTA to the 
enzyme (data not shown). 
In the first report of the inhibition of LTAJ hydrolase 
activity by bestatin it was shown that epibestatin did not 
inhibit enzyme activity in contrast to bestatin and cap- 
topril [20]. This result was confirmed for the LTA, 
hydrolase activity in our human leukocyte cytosolic 
fraction (Table I). As demonstrated in Table 1, in com- 
plete agreement with the previous study [20], bestatin 
was a more potent inhibitor than captopril, while epi- 
bestatin, up to a concentration of 100 PM, showed no 
inhibition of LTB,, formation. The profile of selective 
inhibition of LTB., formation by these compounds 
correlated well with their inhibition of [‘HILTA, label- 
ing of the enzyme (Fig. 4). Quantitation of VI-I] in- 
corporation into LTA, hydrolase by laser dcnsitometric 
scanning of the fluorograph shown in Fig. 4 and also 
from a number of other fluorographs gave averages of 
89% (+/- 5%, S.E.M.), -10% (+/- 28% S.E.M.), and 
80% (I-/- 15%, S.E.M.) for inhibition of [“HILTA la- 
beling of LTA., hydrolase by 100 PM bestatin, 100 /lM 
epibestatin and 100 PM captopril, respectively. These 
values are in close agreement with the selectivity of 
inhibition of LTB formation by these compounds 
(Table I). 
LTAs had previously been shown to be both a sub- 
strate and an inhibitor of LTA4 hydrolase [24]. In addi- 
tion, LTAS has been shown to inhibit covalent coupling 
of [3H]LTA1 to LTAl hydrolase [24]. In our human 
cytosoiic fraction, besiatin inhibited LTBs formation 
from LTAS in a concentration-dependent fashion with 
50% inhibition at approximately 20 ,uM bestatin (Table 
1 and data not shown). E.pibestatin at 100 PM con- 
1 10 100 
Bestatin (uM) 
Fig. 3. Inhibition by bcstatin ol‘]‘H]LTA, labelingoThum;tn leukocyte 
LTA, hydrolasc. A human Icukocytc cytosol fraction (3060% am- 
monium sulphate-prccipitatcd proteins) was prc-incubated with 
DMSO control (+) or varying concentrations of bcstatin in DMSO 
followed by incubation with [“HILTA, as described in Matcrials and 
Methods. The intensity orthe [“HILTA,-labeled LTAJ hydrolasc band 
was quuntitatcd by dcnsitomctric analysis 01’ the fluorograph and 
cxpresscd as % or control labeling. The inset shows the LTA, 
hydrolasc region from the fluorograph with boiled cnzymc DMSO 
control (-), the DMSO control (+). and 0.5/M (I), I PM (2). 5 /fM 
(3). IO yM (4). 20 PM (5). 50 PM (6) and 100 yM (7) bcstatin prc- 
incubations, The graph is reprcscntativc or 2 such titrations vs. 
rH]LTA, and 2 similar titrations vs. pHILTAd methyl ester. 
centration showed no inhibition of LTBS formation 
from LTAS (Table 1). 
4. DISCUSSION 
The intriguing discovery in 1990 that in addition to 
its epoxide hydrolase activity LTAa hydrolase has a 
zinc-dependent aminopeptidase activity has resulted in 
considerable interest in the significance of these two 
activities for the one enzyme [15-181. Professor Dcngt 
Samuelsson originally disclosed data on October 2, 
1990 at the New York Academy of Science and British 
Medical Society conferences on ‘Advances in the Un- 
derstanding and Treatment of Asthma confirming that 
LTAl hydrolase contains 1 mol of zinc per mol of 
enzyme. He presented more studies demonstrating the 
importance of the zinc binding domain of LTAJ 
loo 100100 lcQlooloo10 1 
-+BEC+BECCC+ 
Fig. 4. Selectivity or inhibition or [‘H]LTAI labeling by bcstatin and 
captopril in contrast to cpibcstatin. A human lcukocytecytosol frac- 
lion (30-60% ammonium sulphatc-precipitated proteins) was prc-in- 
cubatcd with DMSO control (+) or IOOpM bestatin (100. B), IOOpM 
cpibestatin (IOO, E), 100 pM c;iptopril (100, C), IO /rM captopril (IO. 
C) or I pM captopril (I, C) rollowcd by incubation with [‘HILTA, as 
described in Materials and Methods. The ligurc shows the lluorograph 
of [‘HILTA,-labeled LTAl hydrolase with boiled enzyme control (-). 
The intensity of 111~ [‘H]LTAa labcling or LTA, hydrolasc was quan- 
titatcd by dcnsitomctry and cxprcsscd as the Q of control labeling. 
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hydroktse for both epoxide hydrolysis and amino- 
peptidase activity in a plenary lecture given on May 16, 
1991 at the Washington Prostuglandins, Leukotrienes, 
Lipoxins and PAF meeting. This lecture, in combina- 
tion with the elegant report documenting the selective 
reversible inhibition of both LTAd hydrolysis nnd ami- 
nopeptide cleavage activities of LTA., hydrolase by bes- 
tatin [30], stimulated the work described in the present 
paper. 
We show here the selective inhibition by bestatin of 
both LTB? and LTBs formation and [‘HILTA, labeling 
of LTA, hydrolase in a human leukocyte cytosolic frac- 
tion. Previously it had been definitively demonstrated 
that the incorporation of [“HILTA methyl ester into 
LTA, hydrolase was stoichiometric with the inactiva- 
tion of the enzyme at concentrations up to 200 ,uM 
vH]LTAA methyl ester [12]. Our method of quantitation 
of [“HILTAd incorporation into LTAJ hydrolase by 
laser densitometric scanning of fluorographs does not 
permit a stroichiometric analysis of the extent of label- 
ing vs. enzyme inhibition. However, the present study 
was carried out at 0. I PM [“HILTA, (or 0.1 yM 
[3H]LTA4 methyl ester), a concentration well below the 
concentration at which stoichiometric labeling and in- 
activation of LTAI hydrolase were previously observed 
[IZ]. Therefore. we believe that in our studies there 
would be little chance for indiscriminate binding of the 
epoxide to the enzyme. 
Our results strongly imply that the site of mechanism- 
based inactivation of the enzyme by LTA.I is the site at 
which bestatin inhibits LTBd and LTBs formation by 
LTA, hydrolase. As would be expected, pre-incubation 
of LTAA hydrolase with bestatin is able to protect the 
enzyme from subsequent mechanism-based inactivation 
by LTAJ (personal communication, Frank Fitzpatrick), 
The present data visualizing inhibition of [3H]LTA4 
labeling of human leukocyte LTAJ hydrolase augments 
and enhances the hypothesis that there is a single site on 
the enzyme that catalyses both epoxide hydrolysis and 
aminopcptide cleavage. If a protein substrate is dis- 
covered for the aminopeptidase activity of LTA4 
hydrolase it would be of grear interest to determine if 
preincubation with this protein would also selectively 
inhibit [‘HILTA, covalent coupling to the enzyme. 
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